Literature DB >> 18931388

Co-encapsulation of gallium with gentamicin in liposomes enhances antimicrobial activity of gentamicin against Pseudomonas aeruginosa.

M Halwani1, B Yebio, Z E Suntres, M Alipour, A O Azghani, A Omri.   

Abstract

OBJECTIVES: The aim of this study was to enhance the antimicrobial efficacy of a liposomal gentamicin formulation with gallium metal (Lipo-Ga-GEN) against clinical isolates of Pseudomonas aeruginosa.
METHODS: Sputum isolates of P. aeruginosa from cystic fibrosis patients were used to determine the MIC and MBC of Lipo-Ga-GEN. P. aeruginosa biofilms were formed and used to compare the minimum biofilm eradication concentration of the conventional drugs with that of Lipo-Ga-GEN. Quorum sensing (QS) molecule reduction of P. aeruginosa was determined by monitoring N-acyl homoserine lactone production using Agrobacterium tumefaciens reporter strain (A136). Viability of the cultured human lung epithelial cells (A549) was determined by Trypan Blue assay in order to assess Ga toxicity.
RESULTS: MIC and MBC values indicated that gentamicin was more effective against a highly resistant strain of P. aeruginosa (PA-48913) when delivered as a Lipo-Ga-GEN formulation (256 mg/L free gentamicin versus 2 mg/L Lipo-Ga-GEN). Lipo-Ga-GEN was the only formulation that completely eradicated biofilms and blocked QS molecules at a very low concentration (0.94 mg/L gentamicin). The decrease in cell viability was less in A549 cells exposed to Lipo-Ga, suggesting that encapsulated Ga is safer.
CONCLUSIONS: The results clearly indicate that the Lipo-Ga-GEN formulation is more effective than gentamicin alone in eradicating antibiotic-resistant P. aeruginosa isolates growing in a planktonic or biofilm community.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18931388     DOI: 10.1093/jac/dkn422

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  32 in total

Review 1.  Whether a novel drug delivery system can overcome the problem of biofilms in respiratory diseases?

Authors:  Kamal Dua; Shakti D Shukla; Rakesh K Tekade; Philip M Hansbro
Journal:  Drug Deliv Transl Res       Date:  2017-02       Impact factor: 4.617

Review 2.  Cystic fibrosis therapeutics: the road ahead.

Authors:  Lucas R Hoffman; Bonnie W Ramsey
Journal:  Chest       Date:  2013-01       Impact factor: 9.410

3.  Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors.

Authors:  Mai Alhajlan; Moayad Alhariri; Abdelwahab Omri
Journal:  Antimicrob Agents Chemother       Date:  2013-04-01       Impact factor: 5.191

Review 4.  Nanoparticle approaches against bacterial infections.

Authors:  Weiwei Gao; Soracha Thamphiwatana; Pavimol Angsantikul; Liangfang Zhang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2014-07-15

5.  Materials innovation for co-delivery of diverse therapeutic cargos.

Authors:  Megan E Godsey; Smruthi Suryaprakash; Kam W Leong
Journal:  RSC Adv       Date:  2013-12-21       Impact factor: 3.361

Review 6.  New antimicrobial strategies in cystic fibrosis.

Authors:  Mireille van Westreenen; Harm A W M Tiddens
Journal:  Paediatr Drugs       Date:  2010-12-01       Impact factor: 3.022

7.  Gallium Potentiates the Antibacterial Effect of Gentamicin against Francisella tularensis.

Authors:  Helena Lindgren; Anders Sjöstedt
Journal:  Antimicrob Agents Chemother       Date:  2015-10-26       Impact factor: 5.191

8.  Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells.

Authors:  Sophie Moreau-Marquis; George A O'Toole; Bruce A Stanton
Journal:  Am J Respir Cell Mol Biol       Date:  2009-01-23       Impact factor: 6.914

9.  Pyoverdine Inhibitors and Gallium Nitrate Synergistically Affect Pseudomonas aeruginosa.

Authors:  Donghoon Kang; Alexey V Revtovich; Alexander E Deyanov; Natalia V Kirienko
Journal:  mSphere       Date:  2021-06-16       Impact factor: 4.389

Review 10.  Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.

Authors:  Matthew N Hurley; Miguel Cámara; Alan R Smyth
Journal:  Eur Respir J       Date:  2012-06-27       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.